HHS Secretary Robert F. Kennedy Jr. said in a statement that the agency had terminated 22 mRNA vaccine development investments because the data show these vaccines “fail to protect effectively against upper respiratory infections like Covid and flu.”
The affected projects totaled nearly 500 million U.S. dollars, he said.
“We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,” he said.
The move signals a broader shift in U.S. federal vaccine development priorities. According to HHS, future efforts will prioritize technologies with stronger safety records and greater transparency in clinical and manufacturing data.
The decision has sparked strong criticism from public health experts and researchers, who warned that retreating from mRNA technology may undermine the country’s ability to respond swiftly to future pandemics.
